[Dynamics of markers of blood inflammation against the background of antibacterial therapy in children with mucoviscidosis, with the various regimens of intake of pancreatic enzymes].
The results of the studies show that patients with mucoviscidosis diagnosed for the first time who do not receive any adequate replacement pancreatic therapy should not be prescribed high doses of pancreatic enzymes along with antibacterial therapy when they are hospitalized on account of exacerbation of the bronchopulmonary process. Sharply increased lipid absorption can cause an aggravation of oxidative stress and impair the patient's state instead of improving it. In our opinion, such patients should be prescribed delayed adequate pancreatic therapy with immediate introduction of high doses of antioxidants (vitamins E, A, C, beta-carotene, etc.). There is no doubt that it is necessary to conduct further research into the problem for a greater number of patients.
N Iu
NIu
Kashirskaia
G V
GV
Shmarina
N I
NI
Kapranov
A L
AL
Pukhal'skiĭ
D000293:Adolescent; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D015415:Biomarkers / Q000097:blood; D002648:Child; D003550:Cystic Fibrosis / Q000150:complications* / Q000188:drug therapy*; D057487:Enzyme Therapy; D005260:Female; D006801:Humans; D007249:Inflammation / Q000175:diagnosis; D018836:Inflammation Mediators / Q000097:blood; D008213:Lymphocyte Activation; D008214:Lymphocytes / Q000097:blood; D008297:Male; D008315:Malondialdehyde / Q000097:blood; D018384:Oxidative Stress; D010179:Pancreas / Q000201:enzymology; D011552:Pseudomonas Infections / Q000150:complications / Q000188:drug therapy*; D011550:Pseudomonas aeruginosa; D013183:Sputum / Q000737:chemistry / Q000166:cytology
D000900:Anti-Bacterial Agents; D015415:Biomarkers; D018836:Inflammation Mediators; D008315:Malondialdehyde